TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Recommendation of “Buy” by Brokerages

TScan Therapeutics, Inc. (NASDAQ:TCRX) has received a consensus rating of “Buy” from the six research firms that are currently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have issued a report on the stock in the last year is $9.33.

A number of research firms have commented on TCRX. Needham & Company LLC reduced their price objective on shares of TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, March 5th. Barclays lowered their price objective on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Morgan Stanley restated an “overweight” rating and issued a $10.00 target price on shares of TScan Therapeutics in a report on Friday. Wedbush reiterated an “outperform” rating and set a $7.00 price target on shares of TScan Therapeutics in a report on Wednesday, March 5th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a research report on Thursday, March 6th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Brown Brothers Harriman & Co. grew its stake in shares of TScan Therapeutics by 88.2% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 143,051 shares of the company’s stock valued at $712,000 after buying an additional 67,027 shares in the last quarter. Great Point Partners LLC grew its position in TScan Therapeutics by 8.0% in the third quarter. Great Point Partners LLC now owns 1,016,375 shares of the company’s stock worth $5,062,000 after acquiring an additional 75,544 shares in the last quarter. MetLife Investment Management LLC increased its stake in shares of TScan Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock worth $116,000 after purchasing an additional 13,164 shares during the last quarter. Checkpoint Capital L.P. bought a new position in shares of TScan Therapeutics during the 3rd quarter valued at $4,110,000. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in shares of TScan Therapeutics in the 3rd quarter valued at $515,000. 82.83% of the stock is owned by institutional investors and hedge funds.

TScan Therapeutics Price Performance

NASDAQ TCRX traded down $0.02 on Friday, reaching $1.77. The company’s stock had a trading volume of 427,359 shares, compared to its average volume of 315,859. TScan Therapeutics has a twelve month low of $1.71 and a twelve month high of $9.69. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. The firm’s 50 day moving average is $2.31 and its two-hundred day moving average is $3.90. The stock has a market cap of $94.47 million, a PE ratio of -1.67 and a beta of 0.91.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Wednesday, March 5th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). The business had revenue of $0.67 million for the quarter, compared to the consensus estimate of $1.43 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. As a group, sell-side analysts predict that TScan Therapeutics will post -1.12 EPS for the current year.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.